Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSanofi ADR

Sanofi ADR

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
47.04 USD 0.13 ( 0.28%)
Last update at 2026-11-06T21:16:00Z
VOLUME
3884859
Market Cap
126376.21M
P/E
18.52

Momentum Score

…

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
45.58
Low
47.13
High
52 Week Price Range
43.86
Low
57.57
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sanofi ADR is a global pharmaceutical company that researches, develops and markets prescription drugs and vaccines, including a major vaccines unit and specialty biologics. Long-term growth drivers include label expansions for its biologics (notably the Dupixent collaboration), vaccine program advancement and a replenishing pipeline from R&D and selective acquisitions that may benefit revenue durability. The company appears positioned to generate diversified revenue and steady cash flow.
Key risks include clinical and regulatory setbacks, patent expirations and biosimilar competition, pricing and reimbursement pressure, and execution or currency exposure from global operations.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
46.91
Dividend Yield
4.28%
Revenue TTM
45166.00M
Revenue Per Share
18.10
Gross Profit TTM
32051.00M
Debt / Equity
0.23
ROE
7.30%
Net Debt
10465.00M
ROCE
11.31%
Diluted EPS TTM
2.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 8268.00M 7798.00M 13804.00M 2822.00M 4405.00M
Minority interest -113.00M -56.00M 146.00M 174.00M 159.00M
Net income 6720.00M 6223.00M 12314.00M 2806.00M 4306.00M
Selling general administrative 10492.00M 9555.00M 9390.00M 9883.00M 9859.00M
Selling and marketing expenses - - 9390.00M 9883.00M 9859.00M
Gross profit 31694.00M 26920.00M 25212.00M 25655.00M 24242.00M
Reconciled depreciation 2053.00M 1580.00M 3684.00M 7452.00M 4279.00M
Ebit 11717.00M 8126.00M 8082.00M 7694.00M 6921.00M
Ebitda 13770.00M 10762.00M 9763.00M 9840.00M 9091.00M
Depreciation and amortization 2053.00M 2636.00M 1681.00M 2146.00M 2170.00M
Non operating income net other - - - 0.00M 0.00M
Operating income 11717.00M 8126.00M 8082.00M 7694.00M 4676.00M
Other operating expenses 33508.00M 30028.00M 29476.00M 30405.00M 29422.00M
Interest expense 440.00M 368.00M 390.00M 444.00M 435.00M
Tax provision 1503.00M 1558.00M 1813.00M 139.00M 481.00M
Interest income 206.00M 40.00M 53.00M 141.00M 164.00M
Net interest income -234.00M -328.00M -337.00M -303.00M -271.00M
Extraordinary items - - - -101.00M -13.00M
Non recurring - - - 0.00M 0.00M
Other items - - - 0.00M 0.00M
Income tax expense 1503.00M 1558.00M 1813.00M 139.00M 481.00M
Total revenue 45389.00M 39175.00M 37369.00M 37631.00M 35677.00M
Total operating expenses 19813.00M 17773.00M 17319.00M 18429.00M 17987.00M
Cost of revenue 13695.00M 12255.00M 12157.00M 11976.00M 11435.00M
Total other income expense net -3449.00M -328.00M 5722.00M -4872.00M -1579.00M
Discontinued operations - - - -101.00M -13.00M
Net income from continuing ops 6833.00M 6279.00M 12350.00M 2938.00M 4423.00M
Net income applicable to common shares 8371.00M 6223.00M 12314.00M 2806.00M 4306.00M
Preferred stock and other adjustments - - - 0.00M 0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 132798.00M 126464.00M 124585.00M 120242.00M 114529.00M
Intangible assets 22629.00M 73573.00M 21640.00M 21407.00M 18421.00M
Other current assets 14601.00M 1239.00M 85.00M 89.00M 83.00M
Total liab 54941.00M 52111.00M 51073.00M 51211.00M 51382.00M
Total stockholder equity 77507.00M 74040.00M 73144.00M 68681.00M 63001.00M
Deferred long term liab - - 6226.00M 7730.00M 6092.00M
Other current liab 16007.00M 13949.00M 425.00M 127.00M 32.00M
Common stock 2526.00M 2530.00M 2522.00M 2527.00M 2518.00M
Capital stock 2526.00M 2530.00M 2522.00M 2527.00M 2518.00M
Retained earnings - 67499.00M - - -
Other liab - - 10835.00M 10954.00M 11426.00M
Good will 43384.00M 49404.00M 49892.00M 48056.00M 44364.00M
Other assets - - 12856.00M 13455.00M 11358.00M
Cash 7441.00M 8710.00M 12736.00M 10098.00M 13915.00M
Total current liabilities 29162.00M 24194.00M 23974.00M 21295.00M 19280.00M
Current deferred revenue - 597.00M 264.00M 319.00M 822.00M
Net debt 10465.00M 9712.00M 8476.00M 12316.00M 9760.00M
Short term debt 4470.00M 2320.00M 4451.00M 3452.00M 2999.00M
Short long term debt 4209.00M 2045.00M 4174.00M 3183.00M 2767.00M
Short long term debt total 17906.00M 18422.00M 21212.00M 22414.00M 23675.00M
Other stockholder equity 4420.00M -871.00M 2437.00M 3998.00M 3795.00M
Property plant equipment - - 11684.00M 11976.00M 10563.00M
Total current assets 42588.00M 30655.00M 34111.00M 30653.00M 33786.00M
Long term investments 3259.00M 2666.00M 9153.00M 7975.00M 7147.00M
Net tangible assets - - 9478.00M 6948.00M 6308.00M
Short term investments 486.00M 270.00M 664.00M 1054.00M 900.00M
Net receivables 10629.00M 11040.00M 374.00M 612.00M 1208.00M
Long term debt 11791.00M 14347.00M 14857.00M 17123.00M 19745.00M
Inventory 9431.00M 9666.00M 20916.00M 19854.00M 18580.00M
Accounts payable 7551.00M 7328.00M 18834.00M 17397.00M 15427.00M
Accumulated other comprehensive income 70561.00M 4882.00M 68185.00M 62156.00M 56688.00M
Common stock total equity - - - - 2518.00M
Non currrent assets other 1370.00M 738.00M -5139.00M -4423.00M -3964.00M
Non current assets total 90210.00M 95809.00M 90474.00M 89589.00M 80743.00M
Capital lease obligations 1906.00M 2030.00M 2181.00M 2108.00M 1163.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2075.00M -311.00M 10233.00M -1058.00M -12872.00M
Change to liabilities 452.00M 451.00M 86.00M 169.00M 270.00M
Total cashflows from investing activities -2075.00M -7298.00M 3588.00M -1212.00M -12866.00M
Net borrowings -1245.00M -2804.00M -1885.00M -491.00M 8722.00M
Total cash from financing activities -5821.00M -7056.00M -6485.00M -4039.00M 3928.00M
Change to operating activities 545.00M 1130.00M 316.00M 421.00M -814.00M
Net income 8371.00M 6223.00M 12294.00M 2754.00M 4306.00M
Change in cash 2638.00M -3817.00M 4488.00M 2502.00M -3390.00M
Begin period cash flow 10098.00M 13915.00M 9427.00M 6925.00M 10315.00M
End period cash flow 12736.00M 10098.00M 13915.00M 9427.00M 6925.00M
Total cash from operating activities 10526.00M 10522.00M 7418.00M 7715.00M 5547.00M
Issuance of capital stock 188.00M 186.00M 203.00M 162.00M 177.00M
Depreciation 3365.00M 3001.00M 3186.00M 3593.00M 3339.00M
Other cashflows from investing activities -16.00M -68.00M -113.00M -94.00M -58.00M
Dividends paid -4168.00M -4008.00M -3937.00M -3834.00M 3773.00M
Change to inventory -927.00M -357.00M -593.00M -547.00M -701.00M
Change to account receivables -777.00M 185.00M -134.00M -462.00M -35.00M
Sale purchase of stock -497.00M -382.00M -822.00M -9.00M -1101.00M
Other cashflows from financing activities 1665.00M -462.00M 2257.00M 1976.00M 7701.00M
Change to netincome -600.00M -230.00M -7851.00M 1630.00M -933.00M
Capital expenditures 1606.00M 1479.00M 1254.00M 1323.00M 1415.00M
Change receivables - - - 0.00M 0.00M
Cash flows other operating - - - 0.00M 0.00M
Exchange rate changes - - - 0.00M 0.00M
Cash and cash equivalents changes - - - 0.00M 0.00M
Change in working capital -1704.00M 1409.00M -325.00M -419.00M -1280.00M
Stock based compensation 245.00M 244.00M 274.00M 252.00M 284.00M
Other non cash items 827.00M 1.00M -7797.00M 3288.00M -2098.00M
Free cash flow 8920.00M 9043.00M 6164.00M 6392.00M 4132.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SNY
Sanofi ADR		 0.13
0.28%		 47.04 18.52 11.27 2.80 1.53 2.77 12.41
LLY
Eli Lilly and Company		 -16.83
1.23%		 1347.90 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson		 3.90
1.43%		 276.22 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc		 3.07
1.07%		 291.31 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation		 6.00
1.28%		 476.00 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Sanofi ADR

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

46, avenue de la Grande Armée, Paris, France, 75017

33 1 53 77 40 00

https://www.sanofi.com

82878

Name Title Year Born
Mr. Paul Hudson CEO & Director 1967
Mr. Jean-Baptiste Chasseloup de Chatillon Exec. VP & CFO 1965
Mr. Laurent Gilhodes Principal Accounting Officer and VP of Corp. Accounting NA
Mr. Bruno Ménard Chief Information officer NA
Dr. Josephine Fubara Chief Science Officer of Consumer Health Care NA
Eva Schaefer-Jansen Head of Investor Relations NA
Mr. Dante Beccaria Global Compliance Officer & VP NA
Mr. Roy Papatheodorou Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity 1978
Mr. Josep Catlla Head of Communications NA
Mr. Pierre Chancel Sr. VP of Global Diabetes and Sr. VP of Global Marketing 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…